Analysts See $0.17 EPS for InterXion Holding NV (INXN), Pacific Biosciences Of California Has 1.1 Sentiment

June 30, 2017 - By Michael Collier

Analysts expect InterXion Holding NV (NYSE:INXN) to report $0.17 EPS on August, 2.They anticipate $0.02 EPS change or 13.33% from last quarter’s $0.15 EPS. INXN’s profit would be $11.98 million giving it 67.38 P/E if the $0.17 EPS is correct. After having $0.16 EPS previously, InterXion Holding NV’s analysts see 6.25% EPS growth. About 20,145 shares traded. InterXion Holding NV (NYSE:INXN) has risen 30.50% since June 30, 2016 and is uptrending. It has outperformed by 13.80% the S&P500.

Pacific Biosciences of California, Inc. designs, develops and makes sequencing systems to help scientists resolve genetically complex problems. The company has market cap of $400.33 million. The Firm is engaged in the development, manufacturing and marketing of an integrated platform for genetic analysis. It currently has negative earnings. The Company’s Single Molecule, Real-Time technology enables single molecule, real-time detection of biological processes.

InterXion Holding N.V. is a provider of carrier and cloud neutral colocation data center services in Europe. The company has market cap of $3.23 billion. The Firm operates through two divisions: France, Germany, The Netherlands and UK, and rest of Europe, which consists of its activities in Austria, Belgium, Denmark, Ireland, Spain, Sweden and Switzerland. It has a 79.83 P/E ratio. The Company’s offering of carrier and cloud neutral colocation services include space, power, cooling and an environment in which to house its customers’ computing, network, storage and information technology infrastructure.

Among 10 analysts covering Interxion Holding NV (NYSE:INXN), 7 have Buy rating, 0 Sell and 3 Hold. Therefore 70% are positive. Interxion Holding NV had 15 analyst reports since August 6, 2015 according to SRatingsIntel. Wells Fargo upgraded InterXion Holding NV (NYSE:INXN) on Wednesday, June 1 to “Outperform” rating. The firm has “Buy” rating given on Thursday, November 5 by Canaccord Genuity. The firm earned “Neutral” rating on Friday, December 2 by Guggenheim. The stock has “Buy” rating by Citigroup on Thursday, November 5. The stock of InterXion Holding NV (NYSE:INXN) has “Outperform” rating given on Tuesday, May 23 by RBC Capital Markets. The rating was upgraded by Evercore on Monday, October 26 to “Buy”. The stock of InterXion Holding NV (NYSE:INXN) has “Buy” rating given on Monday, April 24 by RBC Capital Markets. The rating was downgraded by Jefferies on Monday, June 13 to “Hold”. The rating was upgraded by Canaccord Genuity on Thursday, August 6 to “Buy”. Barclays Capital initiated it with “Overweight” rating and $33 target in Monday, September 28 report.

About 56,335 shares traded. Pacific Biosciences of California (PACB) has declined 59.88% since June 30, 2016 and is downtrending. It has underperformed by 76.58% the S&P500.

Analysts await Pacific Biosciences of California (NASDAQ:PACB) to report earnings on August, 3. They expect $-0.24 earnings per share, down 14.29% or $0.03 from last year’s $-0.21 per share. After $-0.26 actual earnings per share reported by Pacific Biosciences of California for the previous quarter, Wall Street now forecasts -7.69% EPS growth.